What exactly did Jefferies do on March 16, 2026 for ANRO analyst rating?

Jefferies maintained a **Buy** rating on March 16, 2026 and raised the price target to **$35**. The note kept the recommendation unchanged while improving the valuation outlook, reflecting confidence in ALTO-207 and Alto’s funding plan.

How should investors interpret the ANRO analyst rating change?

A maintained Buy with a raised price target suggests confidence, not lowered risk. Investors should combine this ANRO analyst rating with Alto’s trial milestones, cash position, and overall biotech volatility before acting.

Does the ANRO analyst rating account for Alto’s recent financing?

Yes. The ANRO analyst rating from Jefferies reflects the **$120 million** private placement, which extends runway and supports the firm’s higher price target while keeping the Buy recommendation.

What is Meyka AI’s view on ANRO after the rating update?

Meyka AI rates **ANRO with a grade of B** based on benchmark comparison, sector performance, growth metrics, and analyst consensus. The grade supports a balanced view but is not financial advice.

Analyst Ratings

Jefferies Maintains Buy on ANRO, PT Raised to $35 on Mar 16, 2026

ByHuzaifa Zahoor March 17, 2026

Jefferies maintained a Buy rating on Alto Neuroscience, Inc. (ANRO) on March 16, 2026, while raising its price target to $35. This ANRO analyst rating update signals continued analyst confidence in Alto’s clinical strategy for ALTO-207. The move was logged at 10:56 AM and accompanied a reported -2.14% intraday change of $-0.53 in the stock. Investors should weigh the rating against Alto’s cash raise and clinical milestones.